Alessandro Bertuccio

Dr. Alessandro Bertuccio

Neurosurgery, "SS Antonio e Biagio e Cesare Arrigo" University Hospital, Alessandria, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
Alessandro BertuccioAlessandro Bertuccio
Alessandro Bertuccio
SMStefano Marasco
Stefano Marasco
YLYaroslava Longhitano
Yaroslava Longhitano
TRTatsiana Romenskaya
Tatsiana Romenskaya
EAElia Angela
Elia Angela
ABAndrea Barbanera
Andrea Barbanera
External ventricular drainage is often considered a life-saving treatment in acute hydrocephalus. Given the large number of discussion points, the ideal management of EVD has not been completely clarified. The objective of this study was to review the most relevant scientific evidence about the management of EVD in its main clinical scenarios. We reviewed the most recent and relevant articles about indications, timing, management, and complications of EVD in neurocritical care, with particular interest in patients with subarachnoid hemorrhage (SAH), severe traumatic brain injury (TBI), and intraventricular hemorrhage (IVH) using the following keywords alone or matching with one another: intracranial pressure, subarachnoid hemorrhage, traumatic brain injury, intraventricular hemorrhage, external ventricular drainage, cerebrospinal shunt, intracranial pressure monitoring, and ventriculoperitoneal shunt. In the management of EVD in SAH, the intermittent drainage strategy is burdened with an elevated risk of complications (e.g., clogged catheter, hemorrhage, and need for replacement). There seems to be more ventriculoperitoneal shunt dependency in rapid weaning approach-managed patients than in those treated with the gradual weaning approach. Although there is no evidence in favor of either strategy, it is conventionally accepted to adopt a continuous drainage approach in TBI patients. Less scientific evidence is available in the literature regarding the management of EVD in patients with severe TBI and intraparenchymal/intraventricular hemorrhage. EVD placement is a necessary treatment in several clinical scenarios. However, further randomized clinical trials are needed to clarify precisely how EVD should be managed in different clinical scenarios.

30 January 2023 in Diseases
Verified
Journal Article
Open access
PDF file
MVMatteo Vitali
Matteo Vitali
SMStefano Marasco
Stefano Marasco
TRTatsiana Romenskaya
Tatsiana Romenskaya
EAElia Angela
Elia Angela
YLYaroslava Longhitano
Yaroslava Longhitano
ABAndrea Barbanera
Andrea Barbanera
Introduction: Traumatic brain injury (TBI) represents a severe pathology with important social and economic concerns, decompressive craniectomy (DC) represents a life-saving surgical option to treat elevated intracranial hypertension (ICP). The rationale underlying DC is to remove part of the cranial bones and open the dura mater to create space, avoiding secondary parenchymal damage and brain herniations. The scope of this narrative review is to summarize the most relevant literature and to discuss main issues about indication, timing, surgical procedure, outcome, and complications in adult patients involved in severe traumatic brain injury, underwent to the DC. The literature research is made with Medical Subject Headings (MeSH) terms on PubMed/MEDLINE from 2003 to 2022 and we reviewed the most recent and relevant articles using the following keywords alone or matched with each other: decompressive craniectomy; traumatic brain injury; intracranial hypertension; acute subdural hematoma; cranioplasty; cerebral herniation, neuro-critical care, neuro-anesthesiology. The pathogenesis of TBI involves both primary injuries that correlate directly to the external impact of the brain and skull, and secondary injuries due to molecular, chemical, and inflammatory cascade inducing further cerebral damage. The DC can be classified into primary, defined as bone flap removing without its replacement for the treatment of intracerebral mass, and secondary, which indicates for the treatment of elevated intracranial pressure (ICP), refractory to intensive medical management. Briefly, the increased brain compliance following bone removal reflects on CBF and autoregulation inducing an alteration in CSF dynamics and so, eventual complications. The risk of complications is estimated around 40%. The main cause of mortality in DC patients is due to brain swelling. In traumatic brain injury, primary or secondary decompressive craniectomy is a life-saving surgery, and the right indication should be mandatory in multidisciplinary medical–surgical consultation.

9 September 2016
Verified
Book Chapter
Closed access
PDF file
Alessandro BertuccioAlessandro Bertuccio
Alessandro Bertuccio
CRChiara Robba
Chiara Robba
GSGiannantonio Spena
Giannantonio Spena
PVPietro Primo Versari
Pietro Primo Versari

1 November 2020 in World Neurosurgery
Verified
Journal Article
Closed access
Alessandro BertuccioAlessandro Bertuccio
Alessandro Bertuccio
AEAngela Elia
Angela Elia
CRChiara Robba
Chiara Robba
GSGiorgio Scaglione
Giorgio Scaglione
GLGian Paolo Longo
Gian Paolo Longo
ABAndrea Barbanera
Andrea Barbanera

23 January 2022 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
AFAntonio Fioravanti
Antonio Fioravanti
AEAngela Elia
Angela Elia
AMAlessandro Morandini
Alessandro Morandini
CVCarlo Valtulina
Carlo Valtulina
Alessandro BertuccioAlessandro Bertuccio
Alessandro Bertuccio

4 July 2025 in Journal of Neurosurgical Anesthesiology
Verified
Journal Article
Closed access
CICarolina Iaquaniello
Carolina Iaquaniello
ESEmanuela Scordo
Emanuela Scordo
MGMarco Gemma
Marco Gemma
VAVanessa Agostini
Vanessa Agostini
Alessandro BertuccioAlessandro Bertuccio
Alessandro Bertuccio
CRChiara Robba
Chiara Robba
Antiplatelet and anticoagulant medications are widely prescribed to the general population for therapeutic and prophylactic purposes in a wide range of diseases, mainly of cardiovascular interest, spanning from acute events such as acute coronary syndromes (ACS), strokes, and thromboembolic disorders to chronic conditions like atrial fibrillation (AF) and peripheral vascular diseases. The management of such therapies is expected to escalate over time due to the aging population, which has a growing need for these medications, and the rising demand for surgical procedures. The management of anticoagulants and antiplatelets still represents a tough challenge for clinicians in elective neurosurgical procedures, where the balance between preventing thromboembolic events and an increased bleeding risk plays a crucial role in all phases of the perioperative setting. Managing antiplatelet and anticoagulant drugs in elective neurosurgery is complex and requires a tailored and multidisciplinary approach. Careful assessment of patient factors, surgery type, and potential risks and benefits is essential. POC testing can be valuable in optimizing therapy management and bleeding risk assessment. This narrative review for clinicians aims to provide an updated overview of the management of these drugs in the perioperative setting of elective neurosurgical procedures. We explored coagulation abnormalities commonly found in neurosurgical patients, the pharmacological profile of each class of drugs, the appropriate management according to the type of procedure (brain or spinal), and the available diagnostic tests, focusing on the application of point-of-care (POC) coagulation testing.